Company
CNSX:MSET
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable best-in-class innovative next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybins in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, covering multiple drug development programs.
65 stories · page 3 of 4
The company is developing intellectual property in two areas it believes are going to be the most valuable, namely, next-generation drugs and processes that can produce them at the lowest possible cost
CEO James Lanthier told investors that the firm has made “tremendous progress” advancing its library of next-generation psychedelic compounds
The Toronto-based psychedelic company said that its benchmark data was determined by establishing standard pharmacokinetic (PK), brain penetration, and drug discrimination data and protocols for LSD, psilocybin, and 5-MeO-DMT
The company says its Family 4 compounds MSP-4019 and MSP-4020 offer a broad range of pharmacological diversity suitable for in-clinic settings
The ETF is an actively managed product that invests in the flourishing psychedelic drugs industry
Due to the strong preclinical efficacy and safety data in support of MSP-4018, combined with its expedited manufacturing process, it believes its Family 4 clinical candidate has the potential to provide a safer and more scalable therapeutic
Mindset Chief Scientific Officer Joseph Araujo said the results "further validate MSP-1014 as an effective second-generation psilocybin-like drug candidate"
Maxim's analysts said: "Mindset is making progress across its families of next-gen psychedelic compounds, demonstrating improved pharmacological and safety profiles across preclinical studies"
MSP-1014 is a novel patent-pending drug candidate that shows potential to be a safer second-generation psilocybin-like therapy with a decreased potential for side effects
The drug discovery and development company said the studies will to enable it "to confirm the psychedelic effect of its novel compounds with greater accuracy"
Head-to-head preclinical comparisons indicated the novel DMT/5-MeO-DMT-inspired analogs showed a significant decrease in serotonergic toxicity, which can cause a range of mild to life-threatening symptoms
Archive
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
The results have meaningful implications for psychedelic-based therapy at low doses, Mindset’s CEO James Lanthier said
Archive
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
The application covers a range of next generation drug candidates, as well as their related chemical process synthesis, composition of matter and therapeutic uses
The three patent applications cover a range of the firm's so-called Family 1 and Family 2 compounds
Results from its preclinical studies on its Family 2 group of novel psilocybin/psilocin analogs and its Family 4 novel DMT/ 5-MeO-DMT analogs demonstrated superior efficacy, safety and shorter duration of action
The psychedelic drug company is pioneering a unique method to synthesize psilocybin and psilocin in a faster and more effective manner
Investors are getting excited about next generation psychedelics that aim to deliver better benefits as medications for big population groups, with full patent protection
Dr. Husain will provide strategic guidance as the company develops a regulatory pathway for its novel psychedelic-based therapeutics to receive US FDA approval for patients suffering from mental illness
